National Institutes of Health

Description

Purpose. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to continue and expand non-clinical and pre-clinical efforts for product development of radiological/nuclear medical countermeasures effective for 1) the mitigation or treatment of acute radiation syndromes and long-term or delayed effects, 2) the treatment of internal radionuclide contamination with decorporation agents, and 3) the determination of individual radiation exposure levels with radiation biodosimetry products for potential use during a radiological emergency.Applications proposing candidate product(s) that mitigate and/or treat acute and long-term radiation injury due to lethal exposures or facilitate the elimination of internal radionuclide contamination; or that propose means of accurately estimating radiation dose received (biodosimetry) are solicited.Applications should support product development efforts leading to the submission of Investigational New Drug Applications (IND) or Investigational Device Exemptions (IDE) to the U.S. Food and Drug Administration (FDA) to facilitate eventual licensure and potential inclusion in the Strategic National Stockpile (SNS). Mechanism of Support. This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I and Phase II applications.

Who can apply

• Small businesses

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV